» Articles » PMID: 19514087

Comparing Children and Adults with Synovial Sarcoma in the Surveillance, Epidemiology, and End Results Program, 1983 to 2005: an Analysis of 1268 Patients

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2009 Jun 11
PMID 19514087
Citations 125
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Synovial sarcoma (SS) is a typical soft tissue sarcoma subtype crosswise between the pediatric and the adult age groups. Less satisfactory overall outcome has been recorded in adult series.

Methods: This study compares clinical features and outcomes of SS across the different age groups, by analyzing 1268 cases, 213 children/adolescents (<or=18 years) and 1055 adults, registered in the Surveillance, Epidemiology, and End Results (SEER) 17 database from 1983 to 2005. Cancer-specific survival estimates were compared with univariate and multivariate models.

Results: No major differences in stage distribution (localized, regional, and distant stage) were observed comparing the 2 age groups. The estimated 5-year cancer-specific survival was 83% for children/adolescents and 62% for adults (P<.001). Female sex, nonblack race, tumors located in the extremities, localized tumors, and tumors <5 cm in size were associated with better survival. In multivariate analysis, adult patients had significantly higher mortality rates than children after adjusting for other variables.

Conclusions: Children and adults with SS have a similar clinical presentation but a dissimilar outcome, suggesting that factors other than unfavorable clinical features might be involved in the unsatisfactory outcome of adult SS patients. It remains to be ascertained whether this difference is related to biological variables or to historically different treatment approaches adopted in pediatric versus adult patients.

Citing Articles

Diagnostic Differentiation Between Two Rare Entities-Metastatic Peritoneal Mesothelioma With Duodenal Involvement and Duodenal Synovial Sarcoma: A Case Report.

Zwetkoff B, Maluf-Filho F, Venco F, Blasbalg R, de Mello E, de Almeida Barros M Cureus. 2024; 16(11):e74764.

PMID: 39735025 PMC: 11682729. DOI: 10.7759/cureus.74764.


Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.

Luk S, IJsselsteijn M, Somarakis A, Acem I, de Bruijn I, Szuhai K Cancer Immunol Immunother. 2024; 74(1):31.

PMID: 39708175 PMC: 11663204. DOI: 10.1007/s00262-024-03868-2.


SS18-SSX drives TYK2 expression to activate STAT3/Bcl2 axis, facilitating apoptosis evasion and advancing synovial sarcoma progression.

Qin W, Peng C, Yang X, Jiang A, Zhong N, Liu Y Cell Biol Toxicol. 2024; 41(1):8.

PMID: 39707021 PMC: 11662063. DOI: 10.1007/s10565-024-09952-8.


Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma.

Patel R, Gopalakrishnan V, Amini B, Lazar A, Lin P, Benjamin R Cancers (Basel). 2024; 16(23).

PMID: 39682304 PMC: 11639992. DOI: 10.3390/cancers16234119.


Comprehensive treatment of primary pelvic synovial sarcoma: A 28-month follow-up case report and review of the literature.

Li Z, Xiao K, Niu S, Zhu Q, Xiao Z, Yang P Heliyon. 2024; 10(19):e38807.

PMID: 39430488 PMC: 11489358. DOI: 10.1016/j.heliyon.2024.e38807.